Key Takeaways Gilead expands pipeline via Ouro Medicines and Arcellx deals to boost immunology and CAR-T portfolio.GILD will add OM336 and anito-cel, with the latter seen as a key catalyst ahead of a 2026 U.S. decision.Arcellx buyout boosts margins by ending profit-sharing, while competition may pressure growth through 2026.Gilead Sciences, Inc. (GILD) is accelerating its external innovation strategy through targeted acquisitions to bolster its pipeline and diversify beyond its dominant HIV franchise.The re ...

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney’s commercial strategy as the Company advances towards the potential commercialization of rilparencel. “Greg is a seasoned commercial biopharma executive with a proven track reco ...

Core revenue for 2025 totaled $29.6 million compared with $32.5 million in 2024, a 9% decline. In the fourth quarter, core revenue was $6.8 million compared with $8.6 million in the prior-year quarter, down 22%.For the full year ended Dec. 31, 2025, MaxCyte reported total revenue of $33.0 million, down from $38.6 million in 2024, a 15% decline. Fourth-quarter total revenue was $7.3 million versus $8.7 million a year earlier, down 16%.MaxCyte (NASDAQ:MXCT) executives told investors the company made “meaningf ...

MaxCyte (NasdaqGS:MXCT) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Company ParticipantsDouglas Swirsky - CFOErik Abdo - Director of Investor RelationsMaher Masoud - President and CEOSean Menarguez - Senior Director of Business DevelopmentVidyun Bais - VP in Equity ResearchConference Call ParticipantsChad Wiatrowski - AnalystDan Arias - Managing Director & Senior Equity Research AnalystJacob Johnson - AnalystMatt Etoch - Research AnalystMatt Hewitt - Senior Research AnalystOperatorPlease note, this con ...

MaxCyte (NasdaqGS:MXCT) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Company ParticipantsDouglas Swirsky - CFOErik Abdo - Director of Investor RelationsMaher Masoud - President and CEOSean Menarguez - Senior Director of Business DevelopmentVidyun Bais - VP in Equity ResearchConference Call ParticipantsChad Wiatrowski - AnalystDan Arias - Managing Director & Senior Equity Research AnalystJacob Johnson - AnalystMatt Etoch - Research AnalystMatt Hewitt - Senior Research AnalystOperatorPlease note, this con ...

MaxCyte (NasdaqGS:MXCT) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Speaker8Please note, this conference is being recorded. Now we'll turn the call over to Erik Abdo with Investor Relations. Please proceed.Speaker3Good afternoon, everyone. Thank you for participating in today's conference call. Joining me on the call from MaxCyte, we have Maher Masoud, President and Chief Executive Officer, Douglas Swirsky, Chief Financial Officer, and Sean Menarguez, Senior Director of Business Development. Earlier to ...

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpointPresented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASNEnded 2025 with $270.0 millio ...

Core Insights - Gilead Sciences, Inc. (GILD) is facing competitive pressures in its cell therapy franchise, which includes Yescarta and Tecartus, leading to a 7% year-over-year sales decline to $1.8 billion in 2025 [1][9] - To address this decline, GILD plans to acquire Arcellx for $7.8 billion, which will enhance its control over the anito-cel therapy and streamline development and commercialization [2][4][9] Sales Performance - Sales from GILD's cell therapy unit decreased by 7% year-over-year to $1.8 billion in 2025, with Yescarta sales down 5% to $1.5 billion and Tecartus sales down 15% to $344 million [1][9] - The decline is attributed to increasing competition from both in-class and out-of-class therapies [1][9] Acquisition Strategy - GILD's acquisition of Arcellx is valued at $115 per share in cash plus a $5 contingent value right, totaling an equity value of $7.8 billion [2] - This acquisition will provide GILD full control over anito-cel, eliminating profit-sharing and enhancing long-term margin potential [4] Pipeline Developments - GILD's subsidiary, Kite, is collaborating with Arcellx to co-develop anito-cel, which has received FDA acceptance for a biologics license application as a treatment for relapsed or refractory multiple myeloma, with a decision expected in December 2026 [3][4] Competitive Landscape - GILD faces strong competition in the cell therapy market from companies like Bristol Myers (BMY) and Novartis (NVS), with BMY's Breyanzi surpassing $1 billion in annualized sales in 2025 [6][7] - NVS's Kymriah recorded sales of $381 million in 2025, reflecting a 14% decline due to competitive pressures [8] Financial Performance - GILD's shares have increased by 30.3% over the past year, outperforming the industry growth of 15.4% [11] - The current price/earnings ratio for GILD is 16.41x forward earnings, higher than its historical mean of 11.32x but lower than the large-cap pharma industry average of 17.89x [13] Earnings Estimates - The bottom-line estimate for GILD in 2026 has increased to $8.66 from $8.60, while the estimate for 2027 has risen to $9.63 from $9.33 [14]

Core Insights - FibroBiologics is expanding its wound care platform to include treatments for acute and chronic burn injuries, leveraging its proprietary fibroblast spheroid technology [1][2] Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, holding over 270 patents related to various therapeutic areas, including wound healing and chronic diseases [6] Technology and Research Findings - The proprietary fibroblast spheroid treatment (CYWC628) demonstrated nearly a four-fold increase in tissue-level IL-10, which supports tissue repair, and a significant reduction in IL-1B, an inflammatory marker in burn wounds [3][4] - These findings suggest that CYWC628 may enhance wound closure and improve the quality of healed tissue by promoting regeneration and reducing inflammation [4] Market Potential - The global burn care market is estimated to be $2.55 billion and is projected to grow to $3.35 billion by 2030, driven by increasing incidence and demand for advanced wound care solutions [5]

Summary of Gilead Sciences FY Conference Call (March 11, 2026) Company Overview - **Company**: Gilead Sciences (NasdaqGS: GILD) - **Key Focus**: Biopharmaceuticals, particularly in oncology and HIV treatment/prevention Core Points and Arguments Financial Performance - Gilead reported an extraordinary performance in 2025, with significant growth in earnings per share (EPS) and strong operating expense control [7] - The company is at the beginning of a long cycle with multiple product launches and the strongest pipeline in its history [7] Product Launches - **Yeztugo**: A once-every-six-month subcutaneous HIV prevention medicine, launched with extraordinary data showing 100% prevention in high-risk populations [23][24] - **Livdelzi**: A drug for liver disease (PBC) that has shown strong initial sales performance [7] - **Anito-cel**: Acquired through a deal with Arcellx for approximately $8 billion, this is a best-in-class BCMA cell therapy for multiple myeloma with a significant commercial opportunity estimated at over $20 billion [9][10] Market Opportunities - The multiple myeloma market is highlighted as a major opportunity, with Gilead's anito-cel showing a differentiated safety profile compared to competitors [11][14] - Gilead's oncology revenues reached approximately $3 billion, representing about 12% of total revenues, with expectations for steady growth in this segment [19][20] Yeztugo Launch Insights - The launch of Yeztugo is tracking well, with $150 million in sales reported for the first year and over 90% payer coverage achieved [24][26] - The company anticipates significant growth, projecting $800 million in sales for the upcoming year, driven by a growing patient base [22][28] Long-term Growth Strategy - Gilead aims to diversify its portfolio beyond HIV, with multiple upcoming product launches across various therapeutic areas, including oncology and liver disease [66][67] - The company has no major patent cliffs until 2036, allowing for sustained growth and investment in its pipeline [67] Challenges and Market Dynamics - The HIV treatment market is expected to shift towards long-acting therapies, with a significant portion of patients currently not diagnosed or not virally suppressed [42][43] - Despite some Medicaid coverage restrictions, Gilead does not foresee a material impact on its business from these changes [46][54] Community Engagement - Gilead is actively working to reach new populations affected by HIV, particularly in underserved communities, through targeted awareness campaigns [61] Additional Important Content - The company is experiencing a shift in the HIV prevention market, with a noted increase in patients starting on Yeztugo who are naive to HIV prevention therapies [25] - Gilead's commercial team is adapting strategies to raise awareness and reduce stigma associated with HIV treatment and prevention [61] - The overall HIV prevention market is expected to grow significantly, with a 50% increase reported from 2024 to 2025 [35][36] This summary encapsulates the key points discussed during the Gilead Sciences FY Conference Call, highlighting the company's financial performance, product launches, market opportunities, and strategic direction.